Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curaleaf HoldingsFRA:2XW +3.99%52 Days Payable is 36.44 as of Jun. 2026, which is 9% below its 10-year median of 40.16. GuruFocus rates FRA:2XW with a GF Score™ of 52/100 and a GF Value™ of €6.61 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 926 Drug Manufacturers companies, Curaleaf Holdings ranks worse than 84.23% on this metric.
The historical rank and industry rank for Curaleaf Holdings's Days Payable or its related term are showing as below:
FRA:2XW'
s Days Payable Range Over the Past 10 Years
Min: 26.01 Med: 40.16 Max: 84.92
Current: 36.65
During the past 12 years, Curaleaf Holdings's highest Days Payable was 84.92. The lowest was 26.01. And the median was 40.16.
FRA:2XW's Days Payable is ranked worse than 84.23% of 926
companies
in the Drug Manufacturers industry
Industry Median: 88.745
vs FRA:2XW: 36.65
Curaleaf Holdings's Days Payable
declined
from Jun. 2025 (42.20) to Jun. 2026 (36.44).
It may suggest that Curaleaf Holdingsaccelerated paying its suppliers.
The historical data trend for Curaleaf Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Curaleaf Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings (FRA:2XW) has a Days Payable of 36.44 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Curaleaf Holdings and its competitors. This is near median its historical median of 40.16. Over the past decade, Curaleaf Holdings' Days Payable has ranged from 26.01 to 84.92. According to the industry distribution chart, Curaleaf Holdings ranks #780 out of 926 companies in the Drug Manufacturers industry, placing it in the top 84.2%.
Is Curaleaf Holdings' Days Payable too high?
Curaleaf Holdings' current Days Payable of 36.44 is near median its 10-year median of 40.16. Over the past 10 years, this metric has ranged from a low of 26.01 to a high of 84.92. The Drug Manufacturers industry median Days Payable is 88.75. Curaleaf Holdings' value of 36.44 is 58.9% below this industry median. Based on the distribution chart, Curaleaf Holdings ranks #780 out of 926 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curaleaf Holdings has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #780 out of 926 companies for Days Payable. This places Curaleaf Holdings in the lower half of its industry. The industry median Days Payable is 88.75. Curaleaf Holdings' value of 36.44 is 58.9% below this benchmark. Historically, Curaleaf Holdings' own Days Payable has ranged from 26.01 to 84.92 over the past decade. While the company's 10-year median is 40.16 vs. the industry median of 88.75, Curaleaf Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.75, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current Days Payable of 36.44 is 58.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Days Payable is 36.44, which is near median its own 10-year median of 40.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (FRA:2XW) is currently considered Modestly Overvalued. The stock's GF Value™ is €6.61, compared to a current price of €8.34 — trading 26.2% above its estimated fair value. The current Days Payable is 36.44, which is near median its 10-year median of 40.16 and 58.9% below the Drug Manufacturers industry median of 88.75. Curaleaf Holdings' overall GF Score™ is 52/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Curaleaf Holdings (FRA:2XW), the current Days Payable is 36.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (FRA:2XW) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of €8.34 is trading 26.2% above its estimated GF Value™ of €6.61.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for FRA:2XW:
Days Payable: 36.44 (near median its 10-year median of 40.16)
GF Value™: €6.61 vs. price of €8.34 (26.2% above fair value)
Industry Position: 58.9% below the Drug Manufacturers median (#780 of 926)
No single metric tells the full story. See the FRA:2XW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
52GF Score
Get the complete analysis for FRA:2XW
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2XW has been successfully added to your 
